Key result
Strategic ICD programming trial protocol aims to evaluate reductions in shock-related morbidity.
Why the study?
Primary prevention ICD patients have a lower incidence of ventricular arrhythmias and likely experience more inappropriate detections, necessitating evaluation of strategic programming to reduce shock therapies.
Does a pre-specified strategic profile of VT/VF detection and therapy settings reduce shock-related morbidity in primary prevention ICD patients?
Cohort (n=1,391)
Yes
Does a pre-specified strategic profile of VT/VF detection and therapy settings reduce shock-related morbidity in primary prevention ICD patients?
The PREPARE study design outlines a prospective cohort trial to evaluate whether standardized, strategic ICD programming can safely reduce shock-related morbidity in primary prevention patients compared to historical controls.
Answers are grounded in this paper and cite their sources.
Strategic ICD programming may reduce inappropriate shocks in primary prevention; leaves open outcome impact and needs randomized confirmation.
BACKGROUND: Implantable Cardioverter Defibrillator (ICD) therapy has been proven to be beneficial and efficacious for the treatment of serious ventricular tachyarrhythmias in primary prevention patients. However, primary prevention patients appear to have a lower incidence of ventricular arrhythmias in comparison to secondary prevention patients and consequently likely experience a higher proportion of detections due to supraventricular arrhythmias. Recent trials have demonstrated that strategic and specific programming choices reduce the number of inappropriate shocks and that anti-tachycardia pacing (ATP) is an effective alternative to shock therapy for many sustained ventricular arrhythmias. METHODS: The Primary Prevention Parameters Evaluation (PREPARE) study is a multi-center cohort study, evaluating the efficacy of a pre-specified strategic profile of VT/VF detection and therapy settings in 700 primary prevention patients in an effort to safely reduce the number of shock therapies delivered. The patients, both with and without cardiac resynchronization therapy, are compared to a well-qualified set (n = 691) of historical controls derived from the MIRACLE ICD and EMPIRIC trials. This manuscript describes the design of the PREPARE study. The study results, to be presented separately, will characterize the efficacy of this programming set (PREPARE) compared with physician-tailored programming (MIRACLE ICD and EMPIRIC).
No takes yet. Share an insight, caveat, or question.
Wilkoff et al. (2006) conducted a cohort in Primary prevention indications for implantable cardioverter-defibrillators (n=1,391). PREPARE VT/VF detection and therapy settings vs. Physician-tailored programming (historical controls) was evaluated on Difference in Morbidity Index incidence density. The PREPARE trial protocol describes a prospective cohort study designed to evaluate whether a pre-specified strategic programming profile for implantable cardioverter-defibrillators reduces shock-related morbidity compared to physician-tailored programming.
Synapse has enriched 10 related papers. Consider them for comparative context: